CANO Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-01-05 | Koppy Brian D | officer: Chief Financial Officer | 701,955 | F-InKind | D | 28,528 | 1.08 | 30,673.31 |
| 2023-01-05 | Aguilar Richard | officer: Chief Clinical Officer | 862,860 | F-InKind | D | 27,010 | 1.08 | 29,041.15 |
| 2023-01-05 | Novell Mark | officer: Chief Accounting Officer | 119,881 | F-InKind | D | 4,538 | 1.08 | 4,879.26 |
| 2023-01-05 | Armstrong David J | officer: See remarks | 480,155 | F-InKind | D | 19,749 | 1.08 | 21,234.12 |
| 2023-01-03 | Hernandez Marlow | director, officer: CEO | 3,680,910 | A-Award | A | 134,660 | 0.87 | 116,750.22 |
| 2023-01-03 | Armstrong David J | officer: See remarks | 499,904 | A-Award | A | 13,006 | 0.87 | 11,276.20 |
| 2022-12-27 | Hernandez Marlow | director, officer: CEO | 22,034,622 | J-Other | A | 11,017,311 | 0.00 | 0.00 |
| 2022-12-27 | Hernandez Marlow | director, officer: CEO | 22,034,622 | J-Other | A | 11,017,311 | 0.00 | 0.00 |
| 2022-12-27 | Hernandez Marlow | director, officer: CEO | 0 | J-Other | D | 11,017,311 | 0.00 | 0.00 |
| 2022-09-01 | Camerlinck Robert | officer: Chief Operating Officer | 23,843,123 | J-Other | A | 25,386 | 0.00 | 0.00 |
| 2022-08-31 | Armstrong David J | officer: See remarks | 486,898 | F-InKind | D | 20,500 | 5.95 | 122,005.75 |
| 2022-08-31 | Novell Mark | officer: Chief Accounting Officer | 124,419 | F-InKind | D | 7,387 | 5.95 | 43,963.73 |
| 2022-08-31 | Koppy Brian D | officer: Chief Financial Officer | 730,483 | F-InKind | D | 13,651 | 5.95 | 81,242.56 |
| 2022-08-10 | Camerlinck Robert | officer: Chief Operating Officer | 23,817,737 | A-Award | A | 250,000 | 0.00 | 0.00 |
| 2022-08-10 | Novell Mark | officer: Chief Accounting Officer | 131,806 | A-Award | A | 24,000 | 0.00 | 0.00 |
| 2022-07-05 | Armstrong David J | officer: See remarks | 507,398 | A-Award | A | 4,828 | 3.52 | 16,994.56 |
| 2022-07-05 | Hernandez Marlow | director, officer: CEO | 3,546,250 | A-Award | A | 29,870 | 3.52 | 105,142.40 |
| 2022-06-07 | Armstrong David J | officer: See remarks | 502,570 | F-InKind | D | 3,254 | 5.14 | 16,709.29 |
| 2022-05-26 | Hernandez Marlow | director, officer: CEO and President | 11,017,311 | C-Conversion | D | 11,017,311 | 0.00 | 0.00 |
| 2022-05-26 | Hernandez Marlow | director, officer: CEO and President | 11,017,311 | C-Conversion | D | 11,017,311 | 0.00 | 0.00 |
| 2022-05-26 | Hernandez Marlow | director, officer: CEO and President | 11,017,311 | C-Conversion | D | 11,017,311 | 0.00 | 0.00 |
| 2022-05-16 | STERNLICHT BARRY S | director, 10 percent owner | 12,854,233 | A-Award | A | 48,077 | 0.00 | 0.00 |
| 2022-05-16 | Gold Lewis | director | 362,902 | A-Award | A | 48,077 | 0.00 | 0.00 |
| 2022-05-16 | TRUJILLO SOLOMON D | director | 166,633 | A-Award | A | 54,808 | 0.00 | 0.00 |
| 2022-05-16 | Morales Angel L | director | 62,902 | A-Award | A | 48,077 | 0.00 | 0.00 |
| 2022-05-16 | Cooperstone Elliot | director, 10 percent owner | 62,902 | A-Award | A | 48,077 | 0.00 | 0.00 |
| 2022-05-16 | MUNEY ALAN | director | 62,902 | A-Award | A | 48,077 | 0.00 | 0.00 |
| 2022-05-16 | Guichelaar Jacqueline | director | 62,902 | A-Award | A | 48,077 | 0.00 | 0.00 |
| 2022-05-16 | Rivera Kim M | director | 62,902 | A-Award | A | 48,077 | 0.00 | 0.00 |
| 2022-05-09 | Koppy Brian D | officer: Chief Financial Officer | 744,134 | F-InKind | D | 40,484 | 4.38 | 177,319.92 |
| 2022-03-21 | Gold Lewis | director | 1,233,085 | C-Conversion | D | 10,000 | 0.00 | 0.00 |
| 2022-03-21 | Gold Lewis | director | 1,233,085 | C-Conversion | D | 10,000 | 0.00 | 0.00 |
| 2022-03-21 | Gold Lewis | director | 1,233,085 | C-Conversion | D | 10,000 | 0.00 | 0.00 |
| 2022-03-17 | Gold Lewis | director | 314,825 | P-Purchase | A | 300,000 | 6.81 | 2,043,000.00 |
| 2022-03-15 | Novell Mark | officer: Chief Accounting Officer | 107,806 | A-Award | A | 50,000 | 0.00 | 0.00 |
| 2022-03-15 | Hernandez Marlow | director, officer: CEO | 139,175 | A-Award | A | 139,175 | 6.03 | 839,225.25 |
| 2022-03-15 | Hernandez Marlow | director, officer: CEO | 3,516,380 | A-Award | A | 624,418 | 0.00 | 0.00 |
| 2022-03-15 | Aguilar Richard | officer: Chief Clinical Officer | 37,320 | A-Award | A | 37,320 | 6.03 | 225,039.60 |
| 2022-03-15 | Aguilar Richard | officer: Chief Clinical Officer | 889,870 | A-Award | A | 171,641 | 0.00 | 0.00 |
| 2022-03-15 | Armstrong David J | officer: See remarks | 27,990 | A-Award | A | 27,990 | 6.03 | 168,779.70 |
| 2022-03-15 | Armstrong David J | officer: See remarks | 505,824 | A-Award | A | 125,474 | 0.00 | 0.00 |
| 2022-03-15 | Novell Mark | officer: Chief Accounting Officer | 6,449 | A-Award | A | 6,449 | 6.03 | 38,887.47 |
| 2022-03-15 | Novell Mark | officer: Chief Accounting Officer | 57,806 | A-Award | A | 28,783 | 0.00 | 0.00 |
| 2022-03-15 | Koppy Brian D | officer: Chief Financial Officer | 36,681 | A-Award | A | 36,681 | 6.03 | 221,186.43 |
| 2022-03-15 | Koppy Brian D | officer: Chief Financial Officer | 784,618 | A-Award | A | 181,280 | 0.00 | 0.00 |
| 2022-02-07 | Gold Lewis | director | 1,223,085 | C-Conversion | D | 1,223,085 | 0.00 | 0.00 |
| 2022-02-07 | Gold Lewis | director | 1,223,085 | C-Conversion | D | 1,223,085 | 0.00 | 0.00 |
| 2022-02-07 | Gold Lewis | director | 158,850 | C-Conversion | D | 158,850 | 0.00 | 0.00 |
| 2022-02-07 | Gold Lewis | director | 158,850 | C-Conversion | D | 158,850 | 0.00 | 0.00 |
| 2022-02-07 | Gold Lewis | director | 1,223,085 | C-Conversion | D | 1,223,085 | 0.00 | 0.00 |
| 2022-02-07 | Gold Lewis | director | 158,850 | C-Conversion | D | 158,850 | 0.00 | 0.00 |
| 2022-01-28 | Cooperstone Elliot | director, 10 percent owner | 14,825 | A-Award | A | 14,825 | 0.00 | 0.00 |
| 2022-01-28 | MUNEY ALAN | director | 14,825 | A-Award | A | 14,825 | 0.00 | 0.00 |
| 2022-01-28 | Gold Lewis | director | 14,825 | A-Award | A | 14,825 | 0.00 | 0.00 |
| 2022-01-28 | TRUJILLO SOLOMON D | director | 111,825 | A-Award | A | 14,825 | 0.00 | 0.00 |
| 2022-01-28 | STERNLICHT BARRY S | director, 10 percent owner | 14,825 | A-Award | A | 14,825 | 0.00 | 0.00 |
| 2022-01-28 | Morales Angel L | director | 14,825 | A-Award | A | 14,825 | 0.00 | 0.00 |
| 2022-01-28 | Guichelaar Jacqueline | director | 14,825 | A-Award | A | 14,825 | 0.00 | 0.00 |
| 2022-01-28 | Rivera Kim M | director | 14,825 | A-Award | A | 14,825 | 0.00 | 0.00 |
| 2022-01-18 | Aguilar Richard | officer: Chief Clinical Officer | 771,229 | A-Award | A | 200,000 | 0.00 | 0.00 |
| 2022-01-18 | Armstrong David J | officer: See remarks | 380,350 | A-Award | A | 50,000 | 0.00 | 0.00 |
| 2022-01-13 | Koppy Brian D | officer: Chief Financial Officer | 603,338 | A-Award | A | 373,972 | 0.00 | 0.00 |
| 2021-12-29 | Aguilar Richard | officer: Chief Clinical Officer | 718,229 | G-Gift | D | 5,000 | 0.00 | 0.00 |
| 2021-12-28 | Aguilar Richard | officer: Chief Clinical Officer | 723,229 | G-Gift | D | 11,000 | 0.00 | 0.00 |
| 2021-12-27 | Aguilar Richard | officer: Chief Clinical Officer | 734,229 | G-Gift | D | 25,000 | 0.00 | 0.00 |
| 2021-12-23 | Aguilar Richard | officer: Chief Clinical Officer | 759,229 | G-Gift | D | 12,000 | 0.00 | 0.00 |
| 2021-12-22 | Aguilar Richard | officer: Chief Clinical Officer | 529,895 | J-Other | A | 119,407 | 0.00 | 0.00 |
| 2021-12-06 | Hernandez Marlow | director, officer: CEO and President | 473,469 | P-Purchase | A | 14,999 | 11.50 | 172,488.50 |
| 2021-12-06 | Hernandez Marlow | director, officer: CEO and President | 2,891,962 | P-Purchase | A | 15,000 | 8.00 | 120,000.00 |
| 2021-12-03 | Hernandez Marlow | director, officer: CEO and President | 458,470 | P-Purchase | A | 22,001 | 11.50 | 253,011.50 |
| 2021-12-03 | Hernandez Marlow | director, officer: CEO and President | 436,469 | P-Purchase | A | 10,000 | 11.50 | 115,000.00 |
| 2021-12-03 | Hernandez Marlow | director, officer: CEO and President | 2,876,962 | P-Purchase | A | 12,500 | 8.75 | 109,375.00 |
| 2021-11-30 | Hernandez Marlow | director, officer: CEO and President | 426,469 | P-Purchase | A | 15,000 | 11.50 | 172,500.00 |
| 2021-11-23 | Hernandez Marlow | director, officer: CEO and President | 411,469 | P-Purchase | A | 20,000 | 11.50 | 230,000.00 |
| 2021-11-23 | Hernandez Marlow | director, officer: CEO and President | 391,469 | P-Purchase | A | 10,000 | 11.50 | 115,000.00 |
| 2021-11-22 | Hernandez Marlow | director, officer: CEO and President | 2,864,462 | P-Purchase | A | 8,000 | 9.65 | 77,200.00 |
| 2021-11-18 | TRUJILLO SOLOMON D | director | 97,000 | P-Purchase | A | 97,000 | 10.55 | 1,023,350.00 |
| 2021-09-21 | Hernandez Marlow | director, officer: CEO and President | 2,856,462 | A-Award | A | 1,339,500 | 0.00 | 0.00 |
| 2021-09-21 | Koppy Brian D | officer: Chief Financial Officer | 190,000 | A-Award | A | 190,000 | 0.00 | 0.00 |
| 2021-09-21 | Novell Mark | officer: Chief Accounting Officer | 29,023 | A-Award | A | 29,023 | 0.00 | 0.00 |
| 2021-09-21 | Aguilar Richard | officer: Chief Clinical Officer | 410,488 | A-Award | A | 285,333 | 0.00 | 0.00 |
| 2021-09-21 | Armstrong David J | officer: See remarks | 300,333 | A-Award | A | 285,333 | 0.00 | 0.00 |
| 2021-09-04 | Hernandez Marlow | director, officer: CEO and President | 70,000 | P-Purchase | A | 70,000 | 10.75 | 752,500.00 |
| 2021-09-04 | Hernandez Marlow | director, officer: CEO and President | 70,000 | P-Purchase | A | 70,000 | 10.75 | 752,500.00 |
| 2021-08-31 | Hernandez Marlow | director, officer: CEO and President | 67,597 | P-Purchase | A | 2,500 | 11.99 | 29,975.00 |
| 2021-08-31 | Hernandez Marlow | director, officer: CEO and President | 46,987 | P-Purchase | A | 40,419 | 11.50 | 464,818.50 |
| 2021-08-31 | Hernandez Marlow | director, officer: CEO and President | 381,469 | P-Purchase | A | 94,311 | 11.50 | 1,084,576.50 |
| 2021-08-31 | Hernandez Marlow | director, officer: CEO and President | 1,516,962 | P-Purchase | A | 5,833 | 11.99 | 69,937.67 |
| 2021-08-30 | Hernandez Marlow | director, officer: CEO and President | 1,511,129 | P-Purchase | A | 1,173,276 | 10.75 | 12,612,717.00 |
| 2021-08-30 | Hernandez Marlow | director, officer: CEO and President | 65,097 | P-Purchase | A | 2,500 | 11.92 | 29,800.00 |
| 2021-08-30 | Hernandez Marlow | director, officer: CEO and President | 6,568 | P-Purchase | A | 3,896 | 11.50 | 44,804.00 |
| 2021-08-30 | Hernandez Marlow | director, officer: CEO and President | 287,158 | P-Purchase | A | 9,091 | 11.50 | 104,546.50 |
| 2021-08-30 | Hernandez Marlow | director, officer: CEO and President | 2,672 | P-Purchase | A | 2,672 | 11.50 | 30,728.00 |
| 2021-08-30 | Hernandez Marlow | director, officer: CEO and President | 278,067 | P-Purchase | A | 6,235 | 11.50 | 71,702.50 |
| 2021-08-30 | Hernandez Marlow | director, officer: CEO and President | 337,853 | P-Purchase | A | 5,833 | 11.87 | 69,237.71 |
| 2021-08-30 | Aguilar Richard | officer: Chief Clinical Officer | 675,940 | P-Purchase | A | 24,777 | 10.75 | 266,352.75 |
| 2021-08-30 | Aguilar Richard | officer: Chief Clinical Officer | 675,940 | P-Purchase | A | 24,777 | 10.75 | 266,352.75 |
| 2021-08-30 | Aguilar Richard | officer: Chief Clinical Officer | 125,155 | P-Purchase | A | 1,749 | 11.93 | 20,865.57 |
| 2021-08-30 | Aguilar Richard | officer: Chief Clinical Officer | 8,121 | P-Purchase | A | 8,121 | 11.50 | 93,391.50 |
| 2021-08-30 | Aguilar Richard | officer: Chief Clinical Officer | 651,163 | P-Purchase | A | 651,163 | 10.75 | 7,000,002.25 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.